Background/Aims: Endotoxemia is a life-threatening situation that signifies a key challenge in the field of intensive care medicine. Proinflammatory mediators produced by macrophages play a key role in endotoxemia. Gelsolin (GSN) is involved in the process of inflammation. Methods: IL-6 and TNF-α in the supernatant were measured with an ELISA kit. NO production was assessed by measurement of nitrite concentration with the Griess assay. si-RNA directed against GSN (si-GSN) was transfected by Lipofectamine. Results: LPS decreased the levels of GSN. Recombinant GSN inhibited the cytokines induced by LPS and rescued mice from LPSinduced death, and si-GSN increased death in the LPS-pretreated mice. Conclusion: GSN exhibited a protective role in endotoxemia.
Gelsolin Inhibits the Inflammatory Process Induced by LPS

Introduction
Endotoxemia is a life-threatening condition that poses a key challenge within intensive care medicine [1] . The major factor contributing to endotoxemia is exposure to LPS and other bacterial components [2, 3] . Innate immune cells, such as macrophages and dendritic cells, initiate the immune response through pattern recognition [4] [5] [6] [7] . In the condition of endotoxemia, LPS activates macrophages to release proinflammatory mediators, resulting in tissue damage. Thus, with improved understanding of the mechanisms of regulation of macrophages, the clinical outcome of endotoxemia patients could improve.
Gelsolin (GSN) is a widely distributed actin-regulating protein that potentially plays an important role in cell motility [8, 9] . GSN is downregulated in various cancers such as prostate cancer, breast cancer, and lung cancer [10] [11] [12] . GSN plays an important role in the inflammation process. Previous studies have shown that plasma GSN is a biomarker of inflammation [13] , and plasma GSN binds actin and bioactive mediators that are used in
Mouse treatment
Mouse peritoneal macrophages were produced by a standard protocol. C57BL/6 mice were purchased from The Animal Center of The Second Military University and kept in pathogen free rooms. A total of 1 ml of 6% starch broth medium was injected into the peritoneal cavity, avoiding the bladder. The inflammatory response was allowed to proceed for 4 days. Mice were euthanized, and 5 ml of heat-inactivated PBS was injected into the abdominal cavity. Then, the abdomen was massaged gently for 3 min prior to collection of the peritoneal fluid. To obtain monolayers of peritoneal macrophages, the cell concentration was adjusted to 1.5 × 10 6 cells/ml in DMEM medium. The cells were permitted to adhere to the substrate by culturing them for 2 hrs at 37˚C. Cells that did not adhere were removed by gently washing them three times with warm PBS. After washing, the remaining cells were more than 90% macrophages. Macrophages were analyzed at this step or cultured in DMEM medium and maintained for several days [21, 22] . The Animal Committee of The Second Military University approved all mouse experiments. For survival analysis, 60 mice (6-8 weeks, male, 20 ± 3 g) were treated with GSN (133 μg/mouse) or Polymyxin B (PMB) (100 μg/mouse) via intraperitoneal injection. A subset of mice was pretreated with LPS (100 μg/mouse), while the control mice were not. The survival status of every mouse was recorded.
Reagents
Recombinant GSN, LPS, and PMB were purchased from R&D Systems (R&D, Shanghai, China). GSN siRNA (si-GSN) was purchased from RiboBio (Guangdong, China).
Assay for cytokines and NO IL-6 and TNF-α in the supernatant were measured with an ELISA kit (BD Biosciences, Beijing, China). NO production was measured through assessment of nitrite concentration with the Griess assay as described previously [23] .
RNA extraction and real time q-PCR analysis
RNA was extracted with the Trizol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's protocol. cDNA synthesis and real-time qPCR were subsequently performed with the Qiagen system using a protocol from previous studies [24] . Real-time quantitative PCR analysis was performed using standard protocols on an Applied Biosystem 7500 Fast Real-Time PCR System (ABI, Foster City, CA, USA).
siRNA transfection
To decrease GSN, siRNA was generated using a Dicer siRNA generation kit (GeneTherapy Systems, SanDiego, CA), according to the manufacturer's protocol. Forward and reverse PCR primers were designed to generate PCR products between 398 bp downstream and 1,046 bp downstream of the first ATG of human GSN cDNA. The forward and reverse primer sequences used were 5'-GCG TAA TAC GAC TCA CTA TAG GGA GAA TGT GCA GCT GGA TGA CTAG-3' and 5'-GCG TAA TAC GAC TCA CTA TAG GGA GAT AAG CTT GCC TTT CCA GAC AAAG-3', respectively. The GSN sequence in the primer was flanked on the 5' end with 20 nucleotides from the T7 RNA polymerase promoter. Human GSN-cDNA was used as the template for PCR. Following PCR, the product (586 bp) was used as a template for in vitro transcription using T7 RNA polymerase to produce dsRNA GSN-related fragments. The resulting material was treated with DNase to remove the DNA template and RNase to remove any ssRNA. The resulting GSN dsRNA was then cut into small segments of diced-siRNA (20-22 bp) using the RNA Dicer enzyme. Green fluorescent protein (GFP) diced-siRNA (Gene Therapy Systems) targeted to GFP was used as a negative control [25] . Si-GSN transfection was performed using Lipofectamine (Invitrogen, Shanghai, China) according to the manufacturer's instructions [26] . The si-GSN and 5% glucose solution were prepared separately and then mixed together for 15 min before being added to the cells for in vitro assays or injected into mouse via tail vein for in vivo experiments.
Western blotting
For whole cell protein extraction, cells lysates were prepared in lysis buffer as previously reported, separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE; 12%), and transferred to PVDF membranes (Millipore, Billerica, MA, USA). Membranes were blocked with 5% non-fat milk for 2 h and incubated with goat polyclonal anti-GSN or anti-actin antibodies (Cambridge, United Kingdom) overnight, followed by horseradish peroxidase-labelled corresponding immunoglobulin G (1:3000) for 1 h. Finally, enhanced chemiluminescence (Pierce, Rockford, IL, USA) was used to visualize the results. Actin was used as the control.
Statistical analysis
A two-tailed Student's t test was used to analyze the differences between the two groups. ANOVA was used to analyze the differences among three groups. Kaplan-Meier analysis was used to evaluate the overall survival of treated mice. All statistical analysis was performed using SPSS Version 19. Values are expressed as the mean ± S.D. from three tests. All values of P < 0.05 are marked with an asterisk and are considered to be statistically significant.
Results
LPS decreases GSN levels in vitro
To investigate the effect of LPS on GSN expression, we stimulated RAW264.7 cells and peritoneal macrophages with LPS (1 μg/ml) for 96 h or 48 h, respectively. The RAW264.7 Fig. 1 . LPS decreased the levels of GSN. After the preparation of RAW264.7 cells and peritoneal macrophages (1 × 10 6 cells/wells), LPS (1 μg/ml) was applied. After LPS treatment, the levels of GSN were measured by ELISA at 0, 6, 12, 48, 72 or 96 hours in RAW264.7 cells and at 0, 12, 24 or 48 hours in peritoneal macrophages (A). RAW264.7 cells and peritoneal macrophages were treated with LPS (10 ng/ ml or 1000 ng/ml), and GSN levels were measured using ELISA. The experiments were performed at least three times. The mean values were compared by T-test or ANOVA. Data are presented as the mean ± s.d, *P < 0.05.
GSN and PMB rescue mice from LPS-induced death
Mice (N = 60) were pretreated with LPS (100 μg/mouse) and equally divided into 3 groups, where they were treated with GSN (133 μg/mouse, 20 mice), Polymyxin B (PMB) (100 μg/mouse, 20 mice), or no treatment (control, 20 mice) via intraperitoneal injection. We found that GSN saved some mice from LPS-induced death. Polymyxin B (PMB) is a cyclic polypeptide antibiotic produced by soil bacterium that is known to block the biological effects of LPS [27] . Here, PMB was injected into mice for protection from LPS-induced death, and we found that PMB also saved mice from LPS-induced death (Fig. 3) .
GSN reduces LPS-induced inflammatory cytokines and NO in vivo
GSN effectively reduced LPS-induced death within mice; therefore, the potential mechanism was investigated. We measured the IL-6, TNF-α and NO levels in serum of the 5 . The effect of LPS on GSN expression. Mice were treated with LPS (100 μg/mouse) or pretreated with LPS (100 μg/mouse) followed immediately by PMB (100 μg/mouse), and 6 h later, the GSN level in serum was measured by ELISA (A). Peritoneal macrophages were transfected with si-GSN for 48 h, and GSN protein expression was tested by western blot (B). si-GSN was transfected into mice by Lipofectamine. The GSN levels in serum at 0, 1, 3, 6, 12, 24, 48, 72, and 96 h were measured by ELISA following a 6 h si-GSN treatment (C). LPS-pretreated mice were injected with si-GSN, and the GSN level in serum was analyzed by ELISA (D). The experiments were performed three times. Data are presented as the mean ± s.d, *P < 0.05. mice and found that GSN decreased the IL-6, TNF-α and NO levels induced by LPS (Fig.  4) . This suggests that GSN did reduce the LPS-induced death by altering the levels of cytokines.
LPS negatively affects GSN levels in vivo
To test the effect of LPS on GSN expression, mice were treated with LPS. We found that LPS treatment significantly decreased the GSN level in serum. However, PMB pretreatment reduced the inhibitory effect of LPS on GSN levels (Fig. 5A) . Next, we applied si-RNA (si-GSN) to down-regulate the GSN level in vitro, as well as in 32 live mice. We found that si-GSN reduced GSN protein expression in peritoneal macrophages (Fig.  5B) . GSN levels in serum were measured, and the si-GSN reduced the GSN level significantly within 24 hrs (Fig. 5C) . Next, the Fig. 6 . si-GSN increased death in the LPS-pretreated mice. LPS-pretreated mice were treated with si-GSN, and the survival status of mice was analyzed by the Kaplan-Meier method (A). Mice were treated with si-GSN, and 12 h later the IL-6, TNF-α and NO levels in serum were analyzed by ELISA or Griess Reagent (B). The experiments were performed three times. Data are presented as the mean ± s.d, *P < 0.05. LPS-pretreated mice were injected with si-GSN, and we observed that the GSN levels in the LPS-pretreated mice were further reduced (Fig. 5D) .
Targeting GSN in vivo with si-GSN accelerates LPS-induced death in mice
The GSN level was down regulated in vivo by si-GSN transfection, and we found increased mortality with si-GSN in the LPS-pretreated mice (Fig. 6A) . It seems that GSN exhibits a protective role in endotoxemia. Then, we measured the IL-6, TNF-α and NO levels in the serum of si-GSN treated mice, and we found that si-GSN induced higher levels of IL-6, TNF-α and NO in LPS-pretreated mice (Fig. 6B) .
Discussion
The role of GSN in the response to LPS was studied, and we found that LPS reduced GSN levels both in vitro and in vivo. GSN reduced the levels of cytokines induced by LPS in vitro and in vivo. Inhibition of GSN levels via si-GSN decreased the survival rate of LPS-pretreated mice while increasing the cytokine levels in the serum of LPS-pretreated mice. Thus, our results suggest that GSN played a protective role in LPS-induced endotoxemia, and GSN may regulate the LPS-TLR4 signaling pathway (Fig. 7) .
In this study, we found that GSN reduced macrophage secretion of IL-6, TNF-α and NO. These cytokines play an important role in the inflammation process. Interestingly, IL-6 is an interleukin that acts as both a pro-inflammatory and an anti-inflammatory cytokine. The cytokine IL-6 is involved not only in inflammation and the response to infection but also in the regulation of metabolic, regenerative, and neural processes [28] . Our data suggest that the pro-inflammatory role of IL-6 was inhibited by GSN.
Macrophages are the major producers of TNF-α and are highly responsive to TNF-α. Importantly, aberrant TNF-α production and TNF receptor signaling have been associated with the pathogenesis of several diseases including rheumatoid arthritis, Crohn's disease, atherosclerosis, psoriasis, sepsis, diabetes, and obesity [29] . Anti-TNF-α drugs have been used to treat rheumatoid arthritis and inflammatory bowel disease. Our data reveal that TNF-α produced by macrophages can be regulated by GSN.
A previous study reported that attenuated expression of GSN was associated with induction of NO synthase in dysfunctional hearts of aging mice exposed to endotoxins [30] . It is possible that NO could regulate the expression of GSN.
Our data suggest that GSN inhibited IL-6, TNF-α and NO secretion by macrophages. However, a previous study showed that plasma GSN improves host lung defense against pneumonia by enhancing macrophage NOS3 function [31] . We suggest that the functions of macrophages inhibited or enhanced by GSN are dependent on the specific inflammatory scenario.
In conclusion, our study highlighted the role of GSN in endotoxemia. We hope that our study may provide insight into the pathogenesis of endotoxemia and enable the identification of potential treatment targets.
